Quantcast

Industry news that matters to you.  Learn more

AmberGen and Mass General License Two Novel Autoantigen Biomarkers for Autoimmune Liver Disease to INOVA Diagnostics

Two novel autoantigen biomarkers for the autoimmune liver disease Primary Biliary Cirrhosis (PBC), discovered by AmberGen, Inc., in collaboration with the Massachusetts General Hospital (MGH), were exclusively licensed to INOVA Diagnostics, Inc., part of the Werfen Group, and a world-leader in clinical assays for autoimmune disease. Discovery of these biomarkers was made possible by the use of AmberGen’s proprietary proteomic biomarker discovery pipeline and funded by an Advanced Technology Small Business Innovation Research (SBIR) grant to AmberGen from the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health. Following the work done by AmberGen and MGH, the biomarkers where subjected to further clinical validation by INOVA.

CXCL10 is a Negative Prognostic Biomarker of Viral Clearance in Chronic HCV Patients

French researchers recently analyzed chronic hepatitis C virus (HCV) patients to identify plasma biomarkers for response to therapy. They identified CXCL10 as a negative prognostic biomarker of viral clearance.